Aurobindo Pharma gets USFDA nod for Isosulfan Blue injection

Announcing the receipt of approval for single-dose vials (50 mg/5 ml), the company said that the product was expected to be launched by March.

February 03, 2016 02:31 pm | Updated 02:31 pm IST - Hyderabad:

Aurobindo Pharma Ltd. on Wednesday said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Isosulfan Blue Injection, 1%, which is used in lymphography procedure.

Announcing the receipt of approval for single-dose vials (50 mg/5 ml), the company said that the product was expected to be launched by March.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product Lymphazurin injection, 1%, of Covidien.

Explaining the use, a release from the company said that upon subcutaneous administration, Isosulfan Blue Injection delineates the lymphatic vessels draining the region of injection.

The approved product had an estimated market size of $ 57 million during the 12 months ended December 2015, the company said quoting IMS data.

This is the 24th ANDA to be approved out of the Aurobindo Pharma's Unit IV formulation facility in Hyderabad, used for manufacturing general injectable products.

Interim dividend

In another announcement, the company said that the Board of Directors meet scheduled on February 9 will consider the proposal of payment of third interim dividend for 2015-16 besides the results for the quarter ended December 2015 (Q3).

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.